Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And how long before the Class Action Suits Begin.../ Hours/Days.....
Seems like Jabitt should be a target personally, but he and his son may just walk away and get hired by a BP co, and leave the SH stuck.
With all the BS and broken contracts, all the lack of any meaningful effort to even work with Relief, that should tank NEURO to less than a buck, IMHO.
https://stockcharts.com/h-sc/ui?s=RLFTF&p=D&b=5&g=0&id=p01849155591
Some encouragement for the Chart Readers.........
And hoping this trend continues back into the 20's plus
changes, thanks for all the good articles and thoughts.
Breaking...........Researchers In Peer-Reviewed Study Call For “IMMEDIATE WITHDRAWAL of mRNA COVID Vaccines For Use in Pregnancy, Those Breastfeeding, Those Of Childbearing Age and Children”
https://www.thegatewaypundit.com/2021/11/breaking-researchers-peer-reviewed-study-call-immediate-withdrawal-mrna-covid-vaccines-use-pregnancy-breastfeeding-childbearing-age-children/
Yes, FDA needs to approve safe effectve AVIPTADIL instead of experimental dangerous deadly JABS .
198 LINKS EXPOSE CRIMINALITY & FRAUD OF GOVERNMENT, BIG PHARMA PHARMACEUTICALS & THE DEADLY NATURE OF THE BIOWEAPON MRNA GENE THERAPY, FAKE “VACCINE” THAT MODERNA, PFIZER, ASTRA ZENECA AND JOHNSON & JOHNSON
https://touchstoneconnect.com/2021/11/01/198-links-expose-the-criminality-fraud-of-u-s-government-big-pharma-pharmaceuticals-the-deadly-nature-of-the-bioweapon-mrna-gene-therapy-fake-vaccine-that-moderna-pfi/
Except for the link to the useless CDC, most of the other links are eye openers, and further proof that therapeutic meds like AVIPTADIL that are safe and effective are needed urgently and the FDA needs to approve them.
Unfortunately its beginning to look like its all about power and money and nothing to do with saving lives.
Almost 200 great links to clearly show the current murderous outrage from vaccines that are not effective, not safe, and not free.
Again...From Cramers Lightening Round........
NRX Pharmaceuticals: “That was a giant pump and dump ... let’s stay away from that.”
Looks like the same thing today............jumps up, sells off.
something smells here, NO WAY this should be valued above RELIEF.
So, Looking for a big jump in RLF or a bigger selloff in Neuro
thanks Penny... A good examination of a bad author.
AND ONE OF THE MOST STUPID and DAMMING PARTS OF THE ARTICLE THAT even MOST GRADE SCHOOL KIDS WOULD DISAGREE WITH IS
because the medicine had missed the pandemic ................LIKE THE PANDEMIC IS OVER ? SURE.
...NRx Pharmaceuticals claims that while Relief was supposed to fund the Aviptadil project, it decided to abandon this program in early 2021 because the medicine had "missed the pandemic".
A RIDICULOUS OUTRAGEOUS LIE IN THAT STATEMENT BY THE AUTHOR...
LOOKS LIKE THE AUTHOR HAS A HONESTY FACTOR EQUAL TO NEURO..
Thanks for the link Vanilla. Much appreciated.
AND IT LOOKS LIKE A PUMP AND DUMP ARTICLE PLANTED BY NEURO...no surprise, AND no dates are given, ("gearing up" is the term) AS SEEMS USUAL FOR THIS GENERIC PUMP.
AND IF THEY WANTED CLARITY/HONESTY THEY WOULD HAVE LISTED THE PATENT ISSUES AND AT LEAST SOME OF THE MAIN ISSUES IN THE LAWSUIT.
THE ARTICLE IS REALLY OUT OF BOUNDS IMHO.....EVEN IMPLYING THAT RELIEF DOES NOT OWN THE PATENT.
All of the above risks are typical for clinical-stage biotechs, but there is one company-specific issue plaguing NRx Pharmaceuticals. Relief Therapeutics, a Switzerland-based biopharmaceutical company, is currently suing NRx Pharmaceuticals. Relief claims that NRx Pharmaceuticals breached the terms of a collaboration agreement the two entities signed in September 2020.
The agreement relates to the development and potential marketing of Aviptadil. However, NRx Pharmaceuticals claims that while Relief was supposed to fund the Aviptadil project, it decided to abandon this program in early 2021 because the medicine had "missed the pandemic." NRx Pharmaceuticals was then left to fund the project by itself, and while Relief claims it still holds rights to the drug, NRx Pharmaceuticals denies this.
Vf ...thanks for the link...
What about the US EUA ?
Is that European EUA for application in 2022 and then for approval in 2023 from the mouth of those at Neuro that void all their signed agreements ?
Or is that from an anon MF poster ?
/s cryptic as usual
Is the CEO out breaking deals made with other companies like
contract manufacturers and or suppliers ?
Putting payables on hold ? Just pay the invoices when you get sued maybe or try to renegotiate the terms and discounts ??
Is 4m a ringer for JJ ?? 10 whole posts...
4m...Here is all you need to know........
https://lastfuturist.com/nrx-pharmaceuticals-is-trying-to-steal-relief-therapeutics-holding-zyesami-patent/
Looks like Way Too many contracts/agreements that have been grossly violated and broken by Neuro............
VF..Please..how about some links....to confirm what you say is clear, current, and true.... and not cryptic or six or nine months old.
NRx Pharmaceuticals is trying to Steal Relief Therapeutics Holding Zyesami Patent
October 16, 2021Michael Spencer
In terms of business ethics, there’s a code of ethics to follow. When $NRXP went up 60% on October 12th, it immediately lost those highs. It’s not rocket science, it’s greed.
NRx continues to pursue regulatory approvals for the COVID-19 drug Zyesami claiming its theirs. NRx revealed that Relief Therapeutics has initiated a lawsuit alleging breaches of their collaboration agreement. Javitt thinks he can swindle Switzerland, and it’s not cool to witness the American pharma industry up close $RLFTF.
$NRXP has about 12,000 followers on Stocktwits, $RLFTF has about half of that, but which do you think is the better stock?
Relief sadly chose the wrong partner. On October 7th, 2021 it announced that it has filed a lawsuit against NeuroRx, Inc. and its Chief Executive Officer, Dr. Jonathan Javitt, for multiple breaches of the Collaboration Agreement between Relief and NeuroRx relating to the development and commercialization of RLF-100(TM) (aviptadil). The complaint was filed in the Supreme Court of the State of New York in Manhattan.
$RLFTF is back down to $0.11, near its pre-pop August, 2020. OTC stocks are still in a major bear market. $NRXP in spite of shady business ethics here, has had a volatile stock on their hands that is prone to major runs, simply because its in the United States. But who really owns the patent?
When lives are at stake there is no time to waste
Relief has a talented team of scientists, determined to do their part to contribute to the fight against the worst healthcare disaster in 100 years, had a brilliant idea to repurpose a legacy compound, RLF-100™ (aviptadil), a synthetic form of a naturally occurring peptide predominantly found in the lung – Vasoactive Intestinal Peptide (VIP) – to protect the lung from injury due to COVID-19.
NRx should not be taking credit for it. Look at the actual partnership details here.
NRx plans to defend itself in the litigation and make counterclaims against Relief Therapeutics. It’s really not what you want to see when Covid-19 lives are at stake. That a doctor is doing this is just incompressible, you can see his LinkedIn here. His is not the owner of Zyesami or its patent holder.
Relief and NeuroRx have taken steps to set up the manufacturing of RLF-100™ to prepare for potential future commercialization. But now NeuroRx is playing dirty.
On October 14th, 2021 an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.
If Zyesami wasn’t incredible, would NRx be doing this to Relief? That’s the thing.
On September 21, 2020, Relief and NeuroRx announced the completion of their partnership agreement for the commercialization of RLF-100™ worldwide. A year later it doesn’t seem as if NRx is staying true to the partnership contract. What exactly?
The complaint alleges that the defendants are in breach of numerous provisions of the Collaboration Agreement, including without limitation (i) by failing to provide Relief with the full data set from NeuroRx’s recently completed phase 2b/3 clinical trial evaluating IV RLF-100(TM) (aviptadil) for the treatment of acute respiratory failure due to COVID-19.
The data and information are required to be provided to Relief by NeuroRx under the Collaboration Agreement and which data and information are required for Relief to seek approval to commercialize the product in Europe, (ii) by failing to allow Relief, despite multiple requests, to conduct a forensic audit of NeuroRx’s books and records to determine how the funds that Relief provided to NeuroRx were actually used.
(iii) By entering into multiple agreements relating to the development of the product subject to the collaboration without Relief’s consent, as required under the Collaboration Agreement, (iv) by engaging in commercialization efforts in territories outside the purview of NeuroRx’s territory under the Collaboration Agreement, and (v) by developing additional COVID-19 treatments in violation of the exclusivity provisions of the Collaboration Agreement. The suit also alleges, among other matters, breaches of the covenant of good faith and fair dealing and tortious interference with prospective economic advantage. The Complaint, among other remedies, seeks damages, an order compelling defendants to comply with multiple provisions of the Collaboration Agreement, and a declaration directing NeuroRx to deliver the entire data set from the Phase 2b/3 clinical trial of intravenously-administering aviptadil to Relief.
Will American greed and lawyers shut out Relief from this though? It’s hard seeing NRx pull off such a stunt.
Obviously we don’t have all the information but Javitt appears to be in breach of contract. “We are disappointed that NeuroRx has continued to refuse to ameliorate their breaches of the Collaboration Agreement,” stated Jack Weinstein, Chief Financial Officer and Treasurer of Relief. “While we continue to hope to settle these matters with NeuroRx, we are compelled to bring this action to preserve our rights under the Collaboration Agreement and to allow us to continue to develop RLF-100(TM) (aviptadil) in a timely manner for the treatment of acute respiratory failure due to COVID-19 in our territories.”
NeuroRx should not be hurting their smaller Swiss partner with these moves. If you bought Relief at $0.60, it’s now down to $0.10. It’s the OTC market at large, and not simply the sly moves of NeuroRx that is to blame. Relief is a small but talented biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet needs. It has a diversified product portfolio, once it outgrows the OTC, it will be a growing company for Switzerland.
These filings stated that NRx sent a letter to shareholders on Wednesday addressing a lawsuit recently initiated by Relief Therapeutics in New York State Court. Relief alleges that NRx “failed to honor its obligations” under a collaboration agreement between the two companies related to the development of Zyesami (aviptadil). We have to put social pressure on Javitt to do the right thing in this regard and not only see the dollar signs $. If this treatment can save lives, it should be able to do so all over the world and especially in Europe from where it comes from.
The Swiss drugmaker was always the patent holder for Zyesami. To assume otherwise is pure deceptive behavior. $NRXP isn’t just volatile because it’s a Covid-19 treatment, it’s volatile because its leadership doesn’t exactly inspire good faith. While I would long-hold $RLFTF, $NRXP has become not much better than a day trade or a one week swing play.
NRx plans to continue the development of Zyesami and pursue regulatory approvals and authorizations for the COVID-19 drug. The company also intends to defend itself in the lawsuit and “assert significant counterclaims against Relief.” It’s hard to see what those might be.
Acer Therapeutics is at least a normal partner, and not the nightmare NRx has been. Relief is the likely global winner here however:
Relief as the patent holder was always the majority share holder. Why does NeuroRx dispute the obvious? Javitt’s antics have likely only delayed things for this treatment which makes the Merck Pill the main treatment in 2022. It’s not good for shareholders of either to disrupt the partnership contract with a lack of transparency.
While the Merck Pill will be more for minor cases, Aviptadil “can even save the lives of patients near death”. Aviptadil “is unique because it was shown specifically to help those patients who were the sickest, they were essentially dying in the ICU ..the study showed 17 out of 21 of these very ill patients survived who were treated with this drug compared to just 5 who didn’t get the medicines so that an 81% survival rate with Aviptadil compared to just 21% who received typical care like steroids, anticoagulants and conversant plasma now again these were the patients who were the absolute sickest who had multiple severe comorbidities they were all in the ICU and they were at the highest risk for death.
If the Delta variant mutates into a more lethal form of Covid-19, Zyesami might actually become a big deal. This has around a 20% chance of happening. Many lawsuits like this one end up with a settlement. Both parties have a vested interest in seeing Zyesami become a commercial success. That’s probably the most important takeaway for investors right now. But if you are a shareholder, you aren’t happy with how this has gone. There is much speculation about it.
NRx Pharmaceuticals announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI (aviptadil) was submitted to the US Food and Drug Administration (FDA), containing documentation that confirmed Nephron Pharmaceuticals is prepared to supply ZYESAMI on a commercial scale. However Relief own the rights at the end of the day.
This module will now be used as part of the FDA’s rolling review process supporting the New Drug Application for ZYESAMI. Take a look at the agreement between NeuroRx and Nephron, sec.gov/Archives/edgar/data. Relief has the patent and licensing for RLF-100.
We need to start thinking more about Treatments for Delta and what comes after Delta.
As this plays out in court, hard to see $NRXP having an incredible success.
We don’t have all the information, so in the end as shareholders we just have to make reasonable assumptions about what’s going on with the information available.
When it’s a matter of life and death, let’s not screw around with people in ICUs or shareholders. If official figures show nearly 5 million deaths, you know the real numbers are at least double or triple that. Nurses are leaving the profession and the ICUs all around the world. Russia, the UK, Turkey and places like Romania still have a lot of cases. In Russia, Mexico, Romania, Iran and other places significant numbers of people continue to pass in ICUs or before they reach them.
https://lastfuturist.com/nrx-pharmaceuticals-is-trying-to-steal-relief-therapeutics-holding-zyesami-patent/
https://lastfuturist.com/nrx-pharmaceuticals-is-trying-to-steal-relief-therapeutics-holding-zyesami-patent/
From and Thanks to ARA1961 over on the Relief board....
A well written article by Michael Spencer.
https://lastfuturist.com/nrx-pharmaceuticals-is-trying-to-steal-relief-therapeutics-holding-zyesami-patent/
thanks to ara!
A good article worth repeating...........
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166393777
this sure doesn't look good for Nrxp.
CEO JJ is NOT a businessman, and he is making all of the classic mistakes made by a rookie business analyst and/or project manager. As a CEO, JJ is a fish out of water, and his numerous rookie mistakes illustrate that. He would be wise to hire a RAM clone to run his business.
I'm in this to make a profit, and JJ is making it rather difficult to achieve that objective. JMHO
Penny....
...I can not disagree with your astute statement.
https://stockcharts.com/h-sc/ui?s=NRXP&p=D&b=5&g=0&id=p91644957840
Cramer on 07/26
NRX Pharmaceuticals: “That was a giant pump and dump ... let’s stay away from that.”
Much as I do not like advice from Cramer and or his Lightening Round, he was right.
Gotta wonder about this outfit now with so many lawsuit issues coming out of the starting blocks.
Nothing new there with NRXP except the statement that
NRx (NRXP) calls Relief’s (OTCQB:RLFTF) demand that the company immediately cease the development of a new Coronavirus vaccine with the Israeli government “especially shocking.”
And THE DEAL BREAKERS @ NRXP SEES NOTHING SHOCKING IN THEIR OWN CASUAL DISREGARD OF COUNTLESS PAGES OF A SIGNED AGREEMENT, CLEARLY BREAKING NUMEROUS KEY CLAUSES OF THE SIGNED CONTRACTS AND AGREEMENTS.
SOMEONE IS LIVING ON A DIRTY ONE WAY STREET AND ITS NOT RLFTF.
changes........so if Fizer is behind this, then there may be some
deep pockets to tap for judgements.
And we know some of the BP are not shy about paying billion dollar judgements and settling out of court big money. A billion here and a billion there.....no big deal SOP.
Some older stuff.
https://www.enjuris.com/blog/resources/largest-pharmaceutical-settlements-lawsuits/
Some of the more recent stuff....for 10 and 50 billion
https://www.reuters.com/business/healthcare-pharmaceuticals/jj-other-drugmakers-face-trial-california-over-claims-they-fueled-opioid-2021-04-19/
https://my.roundup-cancer-claim.org/?utm_source=google&network=g&keyword=roundup%20lawsuit&matchtype=b&targetid=kwd-299184964443&utm_campaign=12999155240&adgroupid=127765416691&creative=520408183359&feeditemid=&device=c&loc_interest_ms=&loc_physical_ms=9022806&placement=&utm_medium=cpc&gclid=EAIaIQobChMIq4ClopPD8wIVamtvBB1LMwWDEAAYAyAAEgKz1_D_BwE
Looks like NRXP is living in a world of complete denial and ignoring reality
The Company vigorously disputes the allegations made in the press release and intends to defend its position in court
tryn2, I'm with you.
No need to own a company that does not honor any of the conditions of its contracts and agreements, IMHO.
Suspecting or Speculating something outrageous, perhaps even fiction, from NRXP at this stage, with all the extreme quiet, and esp wth the past history now clearly revealed.
EXHIBIT LIST DOCS ...thanks to rant_and_roll on a yh@@ board
https://iapps.courts.state.ny.us/nyscef/DocumentList?docketId=pgGwqeBmpZCRBLxrnghRIA==&display=all&courtType=New%20York%20County%20Supreme%20Court&resultsPageNum=1
Talk about no cooperation at all....
evidently its completely ignore, delay, and or stall tactics by NRXP.
it sure looks like someone is NOT abiding by the agreements / contracts
Could NRXP become a stock trading under one dollar.....???
Seems like there is not any good reason to own this stock right now.
Nice Summary of the Issues From Penny W and
the unbelievably quiet at NRXP does not reflect well for them..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166274806
Plaintiffs respectfully request relief as follows:
a. An award of damages in an amount exceeding $500,000 to be determined at trial;
b. An award of punitive damages;
c. An order compelling Defendants to perform under the Collaboration Agreement including, among other relief:
i. An order enforcing the territorial limits of the Collaboration Agreement and prohibiting Defendants from engaging in any commercialization efforts for aviptadil in any country other than the United States, Canada, or Israel;
ii. An order enforcing the territorial limits of the Collaboration Agreement and prohibiting Defendants from engaging in any commercialization efforts for BriLife;
iii. An order requiring Defendants to submit detailed budget proposals for any clinical trials related to the Collaboration Agreement to Relief's Board of Directors;
iv. An order prohibiting Defendants from entering into third party agreements without Relief's consent as required by Section 5 of the Collaboration Agreement;
v. An order compelling Defendants to allow Plaintiffs access to, and an audit of, Defendants' books and financial records as set forth in Exhibit D;
vi. An order compelling Defendants to share information and collaborate with Relief as required by Section 7 of the Collaboration Agreement;
vii. An order compelling Defendants to produce any and all information licensed from SUNY Stonybrook to Relief; and,
viii. An order specifically enforcing the exclusivity provisions of the Collaboration Agreement;
d. A declaration that the Collaboration Agreement provides Relief with the right to access any and all data related to clinical trials of aviptadil in the United States that have been conducted by, in collaboration with, or at the direction of, NeuroRx and/or its affiliates;
e. An accounting;
f. An award of Relief's costs and attorney's fees;
g. An award of pre-judgment and post-judgment interest on the foregoing sums at the highest rate permitted by law; and,
h. Any further and additional relief that the Court deems just and proper.
Jury Trial Demand
Plaintiffs request a jury trial on all issue so triable.
Dated: October 6, 2021
Respectfully submitted,
/s/ Frederick Andrew Braunstein
Craig Weiner
Frederick Andrew Braunstein
Alexander Newman
AKERMAN LLP
1251 Avenue of the Americas
Suite 3700
New York, NY 10020
Phone: (212) 880-3800
craig.weiner@akerman.com
frederick.braunstein@akerman.com
alexander.newman@akerman.com
Attorneys for Plaintiffs
It looks like RLFTF Might need a forensic audit of all financial activity by all of those individuals involved a NRXP.
Impossible to disagree with you on this point.
A "no response" by NRXP to a lawsuit like this is deafening quiet and reflects very poorly on NRXP. Trust, honor, reputation, and reliability are in question now for those at the top of this business.
thanks PennyWorld, A very good summary.
DISHONEST AND UNTRUSTWORTHY !!!
the non response to the lawsuit speaks volumes.
BOARD OF DIRECTORS AT NRXP SHOULD OUT THOSE IN CHARGE OF THIS FRAUD UNLESS THEY ARE ALSO PART OF THIS FRAUD
Companies or People that TRUST/HONOR the agreements/words/contracts of NRXP and would be willing to work with a company like NRXP might be very limited going forward.
One would need to ask why any contract or agreement signed today would have any greater meaning than what was agreed to yesterday to NRXP.
Going forward why would NRXP honor anything agreed to with anyone or any business, based on what is their past obligations being pretty much completely ignored. ???
It appears very clear right now, that those that had signed contracts and or agreements with RLFTF had NO intention of honoring any of them, and that was, no doubt, even before the involvement of what was eventually big rock/ and then NRXP .
Sad to say, the moral fiber of some is absolutely sickening.
Might explain the attempted vaccine tie in with Israel.
Hope they makes lots on the vaccines so they will be able to pay RLFTF lots of damage awards and penalties.
Vermont — 76% of September Covid deaths were Fully Vaccinated…
https://citizenfreepress.com/breaking/vermont-76-of-september-covid-deaths-were-fully-vaccinated/
THE MOST HIGHLY VAXXED STATE IN THE NATION AND COVID IS SURGING. GO FIGURE. !!!
MAYBE THE FDA NEEDS TO TRIPLE AND QUADRUPLE VAX BY MANDATE IN VERMONT................
VAXX THE POOR FOLKS TO DEATH, AND THE CASE COUNT WILL DROP AFTER ALL DIE OF COVID, AND MAYBE, JUST MAYBE SOMEONE IN THE GOVERNMENT WILL
ACTUALLY ACQUIRE SOME LOGIC AND SOME HONEST SCIENCE.
A LOT BETTER TO APPROVE AVIPTADIL AND ZYESAMI IF THE FDA IS ACTUALLY FOLLOWING THE SCIENCE....SO FAR ITS A BAD NIGHTMARE WITH THE VAX.
Now a rational logical person might ask why does the FDA approve BP shots that are being mandated to be taken in some areas and companies, when it is known to cause serious side effects and deaths, it is ineffective longer term, charts and evidence indicate it increases the viral load count spreading the virus further, it may degrade the natural immune system longer term, the long term side effects are unknown, and it may require semiannual/annual injections for antibody dependent enhancement, plus the BP companies have proven to have millions of doses of product made defectively.
And these BP companies are exempted from any and all liability, death or serious injury.
At best it has known problems with massive numbers of serious side effects and deaths documented on rumble.com and bitchute.com, plus being listed on openvaers, the gov vaccine adverse event reporting system, not to mention other documentation.
YET, the FDA has still has not approved a perfectly safe very effective treatment option in AVIPTADIL and ZYESAMI.
Time to ask WHY !!!!! Call your senators and congressmen. Demand approval for RLFTF and NRXP.
Evidently still problems with Merkmectin, and hot on its heels Fizermectin, which is ANOTHER Protease Inhibitor, like Ivermectin, which is used by 1.3 BILLION people in India.
APPROVAL OF AVIPTADIL/ZYESAMI IS NEEDED QUICKLY....FDA IS STARTING TO LOOK LIKE ITS BEEN ASLEEP UP TO THIS POINT .
https://www.zerohedge.com/news/2021-10-01/mercks-therapeutics-waiting-wings-faucis-removal
Merck's Molnupiravir News
This is a drug with known mutagenicity. Ironically Merck’s inclusion criteria in ALL their clinical trials required participants to not have sex. This includes the clinical trial for prophylaxis. Perhaps they want to avoid the potential of birth defects so this drug is clearly not going to appeal to anyone building a family or engaging in intercourse.
From HIV/AIDS to COVID-19: Vaccines Fail to Impress
The government has a very flawed strategy that the vaccines will fix all.
Therapy Ignorance Costing American Lives and Trillions of Dollars
Changes IV, thanks. Very Interesting.
Penny, you are right. Time to shut up or put up some facts. Time for some evidence and proof or one can only conclude.............. that type of statement is 1) little more than mindless negative speculation intended to push prices lower for shorts, or 2) an outrageous lie, or 3) it is based on inside information and ILLEGALLY made for the benefit of shorts.
SENATOR ON NATURAL IMMUNITY PROTECTS AGAINST DELTA BETTER THAN
THE JAB.
https://www.zerohedge.com/covid-19/sen-johnson-health-agencies-are-ignoring-natural-immunity
https://www.theepochtimes.com/previous-covid-19-infection-protects-against-delta-variant-better-than-pfizer-vaccine-study_3967844.html
AND THEY WANT TO STAB THE CHILDREN
BUT HAVE NOT APPROVED SAFE MEDS LIKE
AVIPTADIL AND ZYESAMI
https://www.theblaze.com/op-ed/horowitz-cdc-endorsed-use-of-ivermectin-for-afghan-refugees
CDC endorsed use of ivermectin … for Afghan refugees!
Op-ed
WHY NOT AVIPTADIL AND OR ZYESAMI IN THE USA ???????
ONLY ENDLESS STABS AND JABS APPROVED BY THE FDA :?????
TOKYO MEDICAL ASSN RECOMMENDS THERAPEAUTICS
https://needtoknow.news/2021/09/tokyo-medical-association-recommends-ivermectin-for-covid-while-the-ama-in-the-us-discourages-its-use/?print=print
WHERE IS THE FDA ON THERAPEAUTICS........???
SAFE EFFECTIVE ONES LIKE AVIPTADIL AND ZYESAMI ?????